Class Action Securities Investigation On Behalf Of CorMedix Inc. Investors Who Acquired The Securities Of CorMedix Inc. Between July 8, 2020 And May 13, 2021, Both Dates Inclusive (the “Class Period”) – Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is making investors of CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) aware that a class action lawsuit was filed on behalf of a class consisting of all persons and entities, other than the CorMedix Defendants, who purchased, or otherwise acquired, the Company’s securities during the Class Period and suffered losses.
According to the class action complaint, throughout the Class Period, the CorMedix Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.
Specifically, the CorMedix Defendants, allegedly, made false and/or misleading statements and/or failed to disclose that (i) deficiencies existed with respect to DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath New Drug Application (“NDA”) for catheter-related bloodstream infections (“CRBSIs”) in its present form; (iii) the CorMedix Defendants had downplayed the true scope of the deficiencies with DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE CORMEDIX SECURITIES BETWEEN JULY 8, 2020 AND MAY 13, 2021, BOTH DATES INCLUSIVE, AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., [email protected], (215) 792-6676, Ext. 804, [email protected], TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.